Literature DB >> 23458891

NAFLD in Asia--as common and important as in the West.

Geoffrey C Farrell1, Vincent Wai-Sun Wong, Shiv Chitturi.   

Abstract

NAFLD--regarded as a consequence of the modern sedentary, food-abundant lifestyle prevalent in the West--was recorded in Japan nearly 50 years ago and its changing epidemiology during the past three decades is well-documented. NAFLD, and its pathologically more severe form NASH, occur in genetically susceptible people who are over-nourished. Asian people are particularly susceptible, partly owing to body composition differences in fat and muscle. Community prevalence ranges between 20% (China), 27% (Hong Kong), and 15-45% (South Asia, South-East Asia, Korea, Japan and Taiwan). This Review presents emerging data on genetic polymorphisms that predispose Asian people to NAFLD, NASH and cirrhosis, and discusses the clinical and pathological outcomes of these disorders. NAFLD is unlikely to be less severe in Asians than in other populations, but the associated obesity and diabetes pandemics have occurred more recently in Asia than in Europe and the USA, and occur with reduced degrees of adiposity. Cases of cryptogenic cirrhosis and hepatocellular carcinoma have also been attributed to NAFLD. Public health efforts to curb over-nutrition and insulin resistance are needed to prevent and/or reverse NAFLD, as well as its adverse health outcomes of type 2 diabetes, cardiovascular events, cirrhosis and liver cancer.

Entities:  

Mesh:

Year:  2013        PMID: 23458891     DOI: 10.1038/nrgastro.2013.34

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  163 in total

1.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

2.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

3.  Risk factors for liver steatosis in obese children and adolescents.

Authors:  Yu-Cheng Lin; Pi-Feng Chang; Shu-Jen Yeh; Kevin Liu; Hui-Chi Chen
Journal:  Pediatr Neonatol       Date:  2010-06       Impact factor: 2.083

4.  Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus.

Authors:  Yuki Kimura; Hideyuki Hyogo; Tomokazu Ishitobi; Yoshitaka Nabeshima; Koji Arihiro; Kazuaki Chayama
Journal:  J Gastroenterol Hepatol       Date:  2011-03       Impact factor: 4.029

Review 5.  The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome.

Authors:  Jung Sub Lim; Michele Mietus-Snyder; Annie Valente; Jean-Marc Schwarz; Robert H Lustig
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-04-06       Impact factor: 46.802

6.  Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD).

Authors:  Winston Dunn; Arun J Sanyal; Elizabeth M Brunt; Aynur Unalp-Arida; Michael Donohue; Arthur J McCullough; Jeffrey B Schwimmer
Journal:  J Hepatol       Date:  2012-04-17       Impact factor: 25.083

7.  Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.

Authors:  Jaana Lindström; Pirjo Ilanne-Parikka; Markku Peltonen; Sirkka Aunola; Johan G Eriksson; Katri Hemiö; Helena Hämäläinen; Pirjo Härkönen; Sirkka Keinänen-Kiukaanniemi; Mauri Laakso; Anne Louheranta; Marjo Mannelin; Merja Paturi; Jouko Sundvall; Timo T Valle; Matti Uusitupa; Jaakko Tuomilehto
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

8.  Association of raised liver transaminases with physical inactivity, increased waist-hip ratio, and other metabolic morbidities in severely obese children.

Authors:  Yung Seng Lee; Betty Lay Kee Kek; Larry Kok Seng Poh; Seang Mei Saw; Kah Yin Loke
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-08       Impact factor: 2.839

9.  Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease.

Authors:  Chung-Huang Tsai; Tsai-Chung Li; Cheng-Chieh Lin
Journal:  South Med J       Date:  2008-09       Impact factor: 0.954

10.  The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls.

Authors:  Luca Valenti; Raffaela Rametta; Massimiliano Ruscica; Paola Dongiovanni; Liliana Steffani; Benedetta Maria Motta; Elena Canavesi; Anna Ludovica Fracanzani; Enrico Mozzi; Giancarlo Roviaro; Paolo Magni; Silvia Fargion
Journal:  BMC Gastroenterol       Date:  2012-08-16       Impact factor: 3.067

View more
  157 in total

Review 1.  Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease.

Authors:  Tannaz Eslamparast; Sareh Eghtesad; Hossein Poustchi; Azita Hekmatdoost
Journal:  World J Hepatol       Date:  2015-02-27

Review 2.  The global NAFLD epidemic.

Authors:  Rohit Loomba; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-17       Impact factor: 46.802

Review 3.  Nonalcoholic fatty liver disease in Asia: emerging perspectives.

Authors:  Wai-Kay Seto; Man-Fung Yuen
Journal:  J Gastroenterol       Date:  2016-09-16       Impact factor: 7.527

Review 4.  The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis.

Authors:  Mithun Sharma; Shasikala Mitnala; Ravi K Vishnubhotla; Rathin Mukherjee; Duvvur N Reddy; Padaki N Rao
Journal:  J Clin Exp Hepatol       Date:  2015-02-16

Review 5.  Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction.

Authors:  Metin Basaranoglu; Gokcen Basaranoglu; Elisabetta Bugianesi
Journal:  Hepatobiliary Surg Nutr       Date:  2015-04       Impact factor: 7.293

6.  Factors associated with significant liver fibrosis assessed using transient elastography in general population.

Authors:  Seng Chan You; Kwang Joon Kim; Seung Up Kim; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Won Jae Lee; Kwang-Hyub Han
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

Review 7.  Role and effective therapeutic target of gut microbiota in NAFLD/NASH.

Authors:  Qun Liu; Shousheng Liu; Lizhen Chen; Zhenzhen Zhao; Shuixian Du; Quanjiang Dong; Yongning Xin; Shiying Xuan
Journal:  Exp Ther Med       Date:  2019-07-17       Impact factor: 2.447

8.  The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis.

Authors:  M Zhou; M T Mok; H Sun; A W Chan; Y Huang; A S Cheng; G Xu
Journal:  Oncogene       Date:  2017-03-20       Impact factor: 9.867

Review 9.  Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Xue-Qun Zhang; Cheng-Fu Xu; Chao-Hui Yu; Wei-Xing Chen; You-Ming Li
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

10.  Prevalence and risk factors of methotrexate hepatoxicity in Asian patients with psoriasis.

Authors:  Chong Meng Yeo; Vui Heng Chong; Arul Earnest; Wei Lyn Yang
Journal:  World J Hepatol       Date:  2013-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.